Welcome to our dedicated page for CALCIMEDICA SEC filings (Ticker: CALC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CalciMedica, Inc. (CALC) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed, clinical-stage biopharmaceutical company focused on CRAC channel inhibition therapies, CalciMedica uses its filings to report financial results, corporate actions, and material developments related to programs such as its Auxora™ clinical trials in acute kidney injury (AKI) with respiratory failure and acute pancreatitis (AP).
Key documents available through EDGAR and summarized here include Form 10-K annual reports and Form 10-Q quarterly reports, which provide detailed discussions of CalciMedica’s business, risk factors, pipeline status, and financial condition. Form 8-K current reports capture specific events such as quarterly earnings press releases, amendments to equity incentive plans approved at the annual meeting, and changes to at-the-market equity offering capacity under the company’s agreement with H.C. Wainwright & Co.
Investors can also monitor S-3 and S-8 registration statements and related exhibits that describe securities offerings and share-based compensation plans, as well as any Form 4 insider transaction reports that may be filed by directors and officers. These filings help clarify how CalciMedica finances its clinical-stage operations, including the use of at-the-market offerings and a disclosed credit facility, and how equity incentives are structured for employees and leadership.
Stock Titan enhances access to these documents with AI-powered summaries that highlight key points from lengthy filings, such as changes in cash runway commentary, updates on the KOURAGE trial, or modifications to capital-raising programs. Real-time updates from EDGAR ensure that new CalciMedica filings appear quickly, while structured views of 10-Ks, 10-Qs, 8-Ks, registration statements, and Form 4 reports allow users to focus on the specific regulatory information most relevant to their analysis of CALC.
CalciMedica, Inc. (CALC) – Form 4 insider filing
Director Alan Glicklich reported the award of four separate stock-option grants on 24 June 2025 under the company’s Amended 2023 Equity Incentive Plan, which was approved by shareholders the same day. All transactions are coded “A” (acquired) and represent incentive compensation rather than open-market buying.
- 10,000 options at an exercise price of $1.53; 1/12th vests monthly over one year from 26 Mar 2025; expires 22 Apr 2035.
- 4,166 options at $1.53; immediately exercisable; expires 22 Apr 2035.
- 15,000 options at $1.53; 1/9th vests monthly over one year from 1 Apr 2025; expires 22 Apr 2035.
- 10,000 options at $1.65; 1/12th vests monthly over one year beginning 24 Jun 2025 (or fully vested by the 2026 AGM); expires 23 Jun 2035.
Following these grants, Glicklich beneficially owns 39,166 derivative securities (options) directly. No common shares were sold or purchased, and no indirect ownership is reported. Because the options are priced near recent market levels and include standard vesting schedules, the filing is primarily routine compensation disclosure with minimal immediate balance-sheet impact but adds modest future dilution potential.
CalciMedica, Inc. (CALC) – Form 4 insider filing dated 26 June 2025
The filing discloses that director Allan Shaw received four separate option grants covering an aggregate 54,844 shares of common stock on 24 June 2025. Three grants, totaling 44,844 options, carry an exercise price of $1.53 and expire on 22 April 2035. A fourth grant of 10,000 options has an exercise price of $1.65 and expires on 23 June 2035.
The awards were approved by the Board on 23 April 2025, but were contingent upon shareholder approval of an amendment to the company’s 2023 Equity Incentive Plan. That amendment was ratified on 24 June 2025, making the options effective the same day.
Vesting schedules are as follows:
- 10,000 options (Grant #1): 1/12 monthly over one year beginning 26 March 2025.
- 8,594 options (Grant #2): fully exercisable immediately.
- 26,250 options (Grant #3): 1/9 monthly over one year beginning 1 April 2025.
- 10,000 options (Grant #4): 1/12 monthly over one year beginning 24 June 2025; fully vested no later than the 2026 annual meeting.
No purchases or sales of already-outstanding common shares were reported, and all securities remain held directly by the reporting person. The filing is a routine incentive-compensation disclosure and does not indicate any change in the director’s ownership of non-derivative equity.
Form 4 highlights for CalciMedica, Inc. (CALC): Director Robert N. Wilson reported the award of four separate stock-option grants on 24 June 2025 following shareholder approval of the amended 2023 Equity Incentive Plan earlier that same day.
Key details: the grants total 68,593 options with exercise prices of $1.53 (three tranches) and $1.65 (one tranche). Vesting schedules differ: (i) 10,000 options vest monthly over 12 months from 26 Mar 2025; (ii) 12,031 options are immediately exercisable; (iii) 36,562 options vest monthly over 12 months from 1 Apr 2025; and (iv) 10,000 options vest monthly over 12 months from 24 Jun 2025 (or fully by the 2026 AGM). All grants expire in April 2035 (first three tranches) or June 2035 (last tranche) and are held directly by the director.
Implications for investors: These are incentive grants—not market purchases or sales—so they do not convey a valuation signal. They do, however, increase the company’s fully diluted share count by roughly 0.6 % (based on ~11 million shares outstanding as of the last 10-Q) and underline ongoing reliance on equity-based compensation. The low strike prices signal CALC’s current trading range and align the director’s upside with shareholders should the share price rise above $1.65 before the 2035 expiry.
CalciMedica, Inc. (CALC) filed a Form 4 reporting new stock-option grants to director and 10% owner Fred A. Middleton. On 06/24/2025 Mr. Middleton was awarded a total of 46,249 director stock options across four separate grants. Three grants carry an exercise price of $1.53 per share and one carries an exercise price of $1.65. All options expire in 2035, providing a 10-year+ exercise window.
The largest tranche—19,687 options—vests in equal monthly installments (1/9) over the year following 01-Apr-2025. Two additional tranches of 10,000 and 6,562 options vest 1/12 monthly after 26-Mar-2025 or are immediately exercisable, respectively. The final grant of 10,000 options vests 1/12 monthly after 24-Jun-2025, but will be fully vested no later than the company’s 2026 annual meeting. All awards were approved by the board on 23-Apr-2025 and became effective after shareholder approval of the amended 2023 Equity Incentive Plan on 24-Jun-2025.
No shares were sold or otherwise disposed of; the transactions are coded “A” (grant). Post-transaction, Mr. Middleton directly holds the same number of options as were granted, reflecting his continued insider ownership. Because the filing reports only option grants and no cash transactions, the immediate impact is limited to potential future dilution and enhanced alignment of director incentives with shareholder value.
CalciMedica, Inc. filed a Form S-8 on 24 June 2025 to register additional shares of its common stock for issuance under two existing employee benefit plans: the 2023 Equity Incentive Plan and the 2023 Employee Stock Purchase Plan. The filing relies on General Instruction E, incorporating the company’s prior S-8 registrations from 2023 and 2024. Standard exhibits accompany the statement, including legal opinions, auditor consent, governing documents, and plan materials. CalciMedica is classified as a non-accelerated filer, smaller reporting company, and emerging growth company. Signatures include CEO A. Rachel Leheny, Ph.D., CFO Stephen Bardin, and the full board of directors.